[144] Artiva Biotherapeutics, Inc. SEC Filing

Rhea-AI Filing Summary

Artiva Biotherapeutics reported a Form 144 notice showing a planned sale of 25,500 common shares held as Restricted Stock Units that were acquired and are to be sold on 08/15/2025. The broker listed is Morgan Stanley Smith Barney LLC and the planned transaction lists an aggregate market value of $68,850 based on 25,500 shares. The filing records 24,425,762 shares outstanding and identifies NASDAQ as the exchange. The filer reports no securities sold in the prior three months and includes the standard representation that the selling person does not possess undisclosed material adverse information.

The notice appears routine: shares arose from company RSUs, the sale is executed through a major broker, and there are no prior sales reported in the three-month lookback period.

Positive

• Transaction is clearly documented with acquisition date, nature (RSUs), broker, and sale date provided
• No prior sales in the past three months, suggesting this is a scheduled disposition rather than frequent insider trading
• Sale size is small relative to shares outstanding (~0.10%), limiting immediate dilutive impact

Negative

• None.

Insights

Securities Analyst

TL;DR Routine insider sale of RSU shares through a broker; modest size relative to outstanding shares.

The filing documents a proposed sale of 25,500 shares from Restricted Stock Units, with an aggregate market value of $68,850. Compared with 24.4 million shares outstanding, the sale is immaterial in dilution terms (~0.10% of outstanding shares). The use of a major broker and the absence of sales in the prior three months point to a scheduled, non-urgent disposition rather than an emergency liquidity event. For investors, this is a routine insider liquidity action with limited direct impact on capitalization or control.

Compliance / Risk Analyst

TL;DR Form 144 conforms to Rule 144 reporting requirements; no red flags in the notice.

The notice indicates shares were acquired and paid on the same date (RSU vesting on 08/15/2025) and that the seller affirms no material nonpublic information. The filing shows "Nothing to Report" for sales in the prior three months and specifies the broker and NASDAQ as venue. From a compliance perspective, the form contains the expected elements: acquisition details, amount, broker, and certifications. There is no indication of irregular transaction structure or contingent payment arrangements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	25500	68850.00	24425762	08/15/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	08/15/2025	Restricted Stock Units	Issuer			25500	08/15/2025	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What is Artiva Biotherapeutics (ARTV) selling according to the Form 144?

The filer plans to sell 25,500 common shares that were acquired as Restricted Stock Units, with the sale dated 08/15/2025.

Through which broker will the ARTV shares be sold?

The filing lists Morgan Stanley Smith Barney LLC as the broker handling the proposed sale.

What is the aggregate market value and how many shares are outstanding?

The aggregate market value is listed as $68,850 and the number of shares outstanding is 24,425,762.

Has the filer sold any Artiva securities in the past three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Does the filer assert possession of material nonpublic information?

No. The filer represents by signature that they do not know any material adverse information about the issuer that is not publicly disclosed.